Last updated on December 2018

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma


Brief description of study

The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Detailed Study Description

This is a multicenter, single-arm, open label, Phase 2 to evaluate efficacy, safety, pharmacokinetics and immunogenicity of E7777 in participants with relapsed or refractory PTCL and CTCL.

Clinical Study Identifier: NCT02676778

Contact Investigators or Research Sites near you

Start Over

Customer Joy Department. EJ

Eisai Trial Site #1
Koto-ku, Japan

Customer Joy Department. EJ

Eisai Trial Site #1
Chuo-ku, Japan
2.56miles

Customer Joy Department. EJ

Eisai Trial Site #1
Bunkyo-ku, Japan
4.4miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.